IL6 and colitis: GSK-J4 has demonstrated anti-inflammatory efficacy in various preclinical models, including colitis, arthritis, and sepsis, by downregulating IL-6, IL-17, and TNF-α, as well as attenuating inflammasome activation [26, 27].